Blueprint reports Phase I data for avapritinib in systemic mastocytosis

Blueprint Medicines Corp. (NASDAQ:BPMC) reported its lead candidate, avapritinib (formerly BLU-285), led to an overall response rate (ORR) of 72% in 18 evaluable patients with advanced systemic mastocytosis (SM) in a Phase I trial. Data were presented at the American Society of Hematology meeting in Atlanta.

The ORR included two complete responses (CR), eight partial responses (PR) and three cases of clinical improvement, defined as meeting one or more of the IWG-MRT-ECNM response criteria in the absence of CR or PR. There were five cases of stable disease. All 32 enrolled patients had greater than 50% decreases in serum tryptase...